- Published on
Diagnostic Tests-: Philadelphia Chromosome
Overview
The Philadelphia chromosome is a well-known cytogenetic abnormality resulting from a reciprocal translocation between chromosomes 9 and 22, written as t(9;22)(q34;q11). This rearrangement fuses the BCR gene on chromosome 22 with the ABL gene on chromosome 9, creating the BCR-ABL oncogene. The resulting abnormal tyrosine kinase drives uncontrolled myeloid cell proliferation. The Philadelphia chromosome is classically associated with chronic myelogenous leukemia (CML) and can be detected through diagnostic methods such as PCR, FISH, or cytogenetic analysis.
When It Is the Most Accurate Diagnostic Test
Diagnostic Tests: Philadelphia Chromosome
Overview
The Philadelphia chromosome is a well-known cytogenet abnormality resulting from a reciprocal translocation between chromosomes 9 and 22, written as t(9;22)(q34;q11). This rearrangement fuses the BCR gene on chromosome 22 with the ABL gene on chromosome 9, creating the BCR-ABL oncogene. The resulting abnormal tyrosine kinase drives uncontrolled myeloid cell proliferation. The Philadelphia chromosome is classically associated with chronic myelogenous leukemia (CML) and can be detected through diagnostic methods such as PCR, FISH, or cytogenetic analysis.
When It Is the Most Accurate Diagnostic Test
Detection of the Philadelphia chromosome is the most accurate diagnostic test when evaluating a patient with suspected CML. Clinically, these cases typically show:
- A markedly elevated white blood cell count
- Predominantly neutrophils, along with other myeloid precursors
- A low leukocyte alkaline phosphatase (LAP) score, which helps distinguish CML from leukemoid reactions
- Symptoms such as fatigue, weight loss, splenomegaly, and early satiety
Beyond diagnosis, the Philadelphia chromosome has prognostic significance. Effective treatment with imatinib (Gleevec) or other BCR-ABL tyrosine kinase inhibitors can reduce or eliminate detectable BCR-ABL transcripts. When the Philadelphia chromosome disappears on molecular testing, it indicates an excellent therapeutic response and a favorable prognosis.
If you’d like, I can also provide a comparison of CML vs. leukemoid reaction, or create a high-yield summary sheet for rapid review.
Detection of the Philadelphia chromosome is the most accurate diagnostic test when evaluating a patient with suspected CML. Clinically, these cases typically show:
- A markedly elevated white blood cell count
- Predominantly neutrophils, along with other myeloid precursors
- A low leukocyte alkaline phosphatase (LAP) score, which helps distinguish CML from leukemoid reactions
- Symptoms such as fatigue, weight loss, splenomegaly, and early satiety
Beyond diagnosis, the Philadelphia chromosome has prognostic significance. Effective treatment with imatinib (Gleevec) or other BCR-ABL tyrosine kinase inhibitors can reduce or eliminate detectable BCR-ABL transcripts. When the Philadelphia chromosome disappears on molecular testing, it indicates an excellent therapeutic response and a favorable prognosis.
0 Comments
